Screener
Stoke Therapeutics, Inc. STOK Common Stock
Common Stock at other companies
Other financials
Where this comes from
Reported directly by Stoke Therapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:CommonStockValue.
The source filing: Stoke Therapeutics, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 4:06 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-211874
| Line item | March 31, 2026 | December 31, 2025 |
|---|---|---|
| Total liabilities | $48,400 | $65,977 |
| Commitments and contingencies (Note 6) | ||
| Stockholders’ equity | ||
| Common stock, par value of $0.0001 per share; 300,000,000 shares authorized, 62,240,347 and 58,921,999 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 6 | 5 |
| Additional paid-in capital | 942,704 | 849,624 |
| Accumulated other comprehensive (loss) income | (115) | 543 |
| Accumulated deficit | (547,718) | (497,715) |
| Total stockholders’ equity | $394,877 | $352,457 |
Item 1. Financial Statements.
FAQ
- What is Stoke Therapeutics, Inc.'s common stock?
- Stoke Therapeutics, Inc. (STOK) reported common stock of $6K in Q1 2026.
- How has Stoke Therapeutics, Inc.'s common stock changed year-over-year?
- Stoke Therapeutics, Inc.'s common stock increased by 20.0% year-over-year, from $5K to $6K.
- What is the long-term trend for Stoke Therapeutics, Inc.'s common stock?
- Over 5 years (2020 to 2025), Stoke Therapeutics, Inc.'s common stock has grown at a 4.6% compound annual growth rate (CAGR), from $4K to $5K.
- What does common stock mean?
- The par value of all common shares issued and outstanding, typically a nominal amount ($0.01 or $0.001 per share).
Ask your AI about Stoke Therapeutics, Inc.'s common stock.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude